New ways of estimating excess mortality of chronic diseases from aggregated data: insights from the illness-death model.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
28 Jun 2019
Historique:
received: 05 04 2019
accepted: 19 06 2019
entrez: 30 6 2019
pubmed: 30 6 2019
medline: 13 9 2019
Statut: epublish

Résumé

Recently, we have shown that the age-specific prevalence of a disease can be related to the transition rates in the illness-death model via a partial differential equation (PDE). The transition rates are the incidence rate, the remission rate and mortality rates from the 'Healthy' and 'Ill' states. In case of a chronic disease, we now demonstrate that the PDE can be used to estimate the excess mortality from age-specific prevalence and incidence data. For the prevalence and incidence, aggregated data are sufficient - no individual subject data are needed, which allows application of the methods in contexts of strong data protection or where data from individual subjects is not accessible. After developing novel estimators for the excess mortality derived from the PDE, we apply them to simulated data and compare the findings with the input values of the simulation aiming to evaluate the new approach. In a practical application to claims data from 35 million men insured by the German public health insurance funds, we estimate the population-wide excess mortality of men with diagnosed type 2 diabetes. In the simulation study, we find that the estimation of the excess mortality is feasible from prevalence and incidence data if the prevalence is given at two points in time. The accuracy of the method decreases as the temporal difference between these two points in time increases. In our setting, the relative error was 5% and below if the temporal difference was three years or less. Application of the new method to the claims data yields plausible findings for the excess mortality of type 2 diabetes in German men. The described approach is useful to estimate the excess mortality of a chronic condition from aggregated age-specific incidence and prevalence data. The article does not report the results of any health care intervention.

Sections du résumé

BACKGROUND BACKGROUND
Recently, we have shown that the age-specific prevalence of a disease can be related to the transition rates in the illness-death model via a partial differential equation (PDE). The transition rates are the incidence rate, the remission rate and mortality rates from the 'Healthy' and 'Ill' states. In case of a chronic disease, we now demonstrate that the PDE can be used to estimate the excess mortality from age-specific prevalence and incidence data. For the prevalence and incidence, aggregated data are sufficient - no individual subject data are needed, which allows application of the methods in contexts of strong data protection or where data from individual subjects is not accessible.
METHODS METHODS
After developing novel estimators for the excess mortality derived from the PDE, we apply them to simulated data and compare the findings with the input values of the simulation aiming to evaluate the new approach. In a practical application to claims data from 35 million men insured by the German public health insurance funds, we estimate the population-wide excess mortality of men with diagnosed type 2 diabetes.
RESULTS RESULTS
In the simulation study, we find that the estimation of the excess mortality is feasible from prevalence and incidence data if the prevalence is given at two points in time. The accuracy of the method decreases as the temporal difference between these two points in time increases. In our setting, the relative error was 5% and below if the temporal difference was three years or less. Application of the new method to the claims data yields plausible findings for the excess mortality of type 2 diabetes in German men.
CONCLUSIONS CONCLUSIONS
The described approach is useful to estimate the excess mortality of a chronic condition from aggregated age-specific incidence and prevalence data.
TRIAL REGISTRATION BACKGROUND
The article does not report the results of any health care intervention.

Identifiants

pubmed: 31253126
doi: 10.1186/s12889-019-7201-7
pii: 10.1186/s12889-019-7201-7
pmc: PMC6599235
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

844

Références

Theor Popul Biol. 1999 Aug;56(1):76-90
pubmed: 10438670
Neurology. 2000;54(11 Suppl 5):S4-9
pubmed: 10854354
Neurology. 2000;54(11 Suppl 5):S10-5
pubmed: 10854355
Diabetologia. 2008 Dec;51(12):2187-96
pubmed: 18815769
BMJ. 2010 Aug 05;341:c3584
pubmed: 20688840
Theor Popul Biol. 2013 Dec;90:29-35
pubmed: 24084064
Theor Popul Biol. 2014 Mar;92:62-8
pubmed: 24333220
Math Med Biol. 2015 Dec;32(4):425-35
pubmed: 25576933
PLoS One. 2015 Mar 06;10(3):e0118955
pubmed: 25749133
PLoS One. 2016 Mar 29;11(3):e0152046
pubmed: 27023438
Dtsch Arztebl Int. 2016 Mar 18;113(11):177-82
pubmed: 27118665
Ann Rheum Dis. 2018 Apr;77(4):e19
pubmed: 28765122
Lifetime Data Anal. 2018 Oct;24(4):743-754
pubmed: 29374340
Nutr Metab Cardiovasc Dis. 2018 Sep;28(9):887-891
pubmed: 29960839
Comput Math Methods Med. 2018 Sep 12;2018:5091096
pubmed: 30275874

Auteurs

Ralph Brinks (R)

Institute for Biometry and Epidemiology, German Diabetes Center, Auf'm Hennekamp 65, 40225, Duesseldorf, Germany. ralph.brinks@ddz.de.
Department and Hiller Research Unit for Rheumatology, University Hospital Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany. ralph.brinks@ddz.de.

Thaddäus Tönnies (T)

Institute for Biometry and Epidemiology, German Diabetes Center, Auf'm Hennekamp 65, 40225, Duesseldorf, Germany.

Annika Hoyer (A)

Institute for Biometry and Epidemiology, German Diabetes Center, Auf'm Hennekamp 65, 40225, Duesseldorf, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH